StockNews.com Begins Coverage on Atrion (NASDAQ:ATRI)

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research note released on Saturday. The firm issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

ATRI stock opened at $459.02 on Friday. Atrion has a 1-year low of $274.98 and a 1-year high of $525.41. The company has a market capitalization of $807.88 million, a price-to-earnings ratio of 43.14 and a beta of 0.69. The business has a 50 day simple moving average of $455.38 and a two-hundred day simple moving average of $424.58.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%. The business had revenue of $48.77 million during the quarter.

Atrion Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were given a dividend of $2.20 per share. The ex-dividend date was Friday, June 14th. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.92%. Atrion’s dividend payout ratio is currently 82.71%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Citizens Financial Group Inc. RI bought a new position in shares of Atrion during the 4th quarter valued at approximately $1,114,000. Penn Mutual Asset Management LLC bought a new position in shares of Atrion during the 4th quarter valued at approximately $1,949,000. Public Employees Retirement System of Ohio bought a new position in shares of Atrion during the 1st quarter valued at approximately $2,299,000. Jump Financial LLC bought a new position in shares of Atrion during the 4th quarter valued at approximately $234,000. Finally, Sei Investments Co. boosted its position in shares of Atrion by 59.7% during the 1st quarter. Sei Investments Co. now owns 1,774 shares of the medical instruments supplier’s stock valued at $822,000 after acquiring an additional 663 shares during the last quarter. 66.19% of the stock is currently owned by institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.